What is Behavidence?
Founded in 2020 by a multidisciplinary team of neuroscientists, physicians, and bioengineers, Behavidence specializes in the development of advanced machine learning tools designed for the remote monitoring of psychiatric and neurological conditions. The company's core value proposition lies in its ability to transform passive digital data into actionable clinical insights, effectively predicting disorders such as depression, anxiety, and ADHD without imposing respondent burden.
The platform serves a diverse array of stakeholders, including health organizations, government entities, and commercial enterprises. By offering real-time feedback and measurement-based outcomes, Behavidence addresses critical gaps in employee wellness, burnout prevention, and clinical intervention, establishing itself as a disruptive force in the digital health landscape.
How much funding has Behavidence raised?
Behavidence has raised a total of $4.3M across 1 funding round:
Angel/Seed
$4.3M
Angel/Seed (2022): $4.3M with participation from Longevity Venture Partners, Welltech Ventures, and Arc Impact
Key Investors in Behavidence
Longevity Venture Partners
Longevity Venture Partners is an early-stage venture capital firm focused on supporting entrepreneurs in the Silvertech, Healthcare, and Wellness sectors.
Welltech Ventures
WellTech Ventures is a leading wellness-focused venture capital fund that invests in visionary entrepreneurs reimagining health and wellness technology.
Arc Impact
Arc Impact invests in promising startups across various sectors, including educational technology, workforce training, healthcare, and assistive technologies.
What's next for Behavidence?
With this major strategic investment, Behavidence is poised to accelerate its product roadmap and expand its footprint in the enterprise wellness market. The company is expected to focus on enhancing its predictive models to support more complex clinical interventions and comorbid condition management. As the demand for objective, data-driven mental health monitoring continues to rise, the firm is well-positioned to leverage its existing partnerships to drive widespread adoption of its digital phenotyping solutions.
Future growth will likely center on refining the privacy-first architecture of its platform, ensuring that as the company scales, it maintains the high standards of data security required by its government and healthcare clients. This strategic positioning suggests a long-term commitment to transforming how mental health is monitored and managed on a global scale.
